Acorda Updates Contraindications & Warnings Sections of Zanaflex Label

Acorda Therapeutics and FDA informed healthcare professionals of changes to the CONTRAINDICATIONS and WARNINGS Sections of the product labeling for Zanaflex (tizanidine hydrochloride) , a drug used to treat spasticity.

In pharmacokinetic studies where tizanidine was coadministered with either fluvoxamine or ciprofloxacin (CYP1A2 inhibitors), the serum concentration of tizanidine was significantly increased and potentiated its hypotensive and sedative effects.

Although there are no clinical studies evaluating the effects of other CYP1A2 inhibitors on tizanidine, coadministration of tizanidine with other CYP1A2 inhibitors (zileuton, other fluroquinolones, antiarrythmics, cimetidine, famotidine, oral contraceptives, acyclovir and ticlopidine) should be avoided.

see also:

Doctors' Letter 'Dear Doctor' Warning to Health Workers on New Labeling for Zanaflex
Acorda Sends Letter Warning Doctors of New Labeling for Zanaflex

Aranesp Aranesp Ineffective in Reducing Red blood Cell Transfusions or Fatigue
Study shows Aranesp ineffective and also causes higher mortality

2007 Health Advisories Pre-made Colistimethate May Link to Cystic Fibrosis Patient's Death
Cystic Fibrosis Patient Dies After Using Pre-Mixed Colistimethate